Form 8-K Prime Medicine, Inc. For: Jul 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
July 8, 2026 12:30 PM EDTTD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).
The analyst comments "PRME announced a positive binding arbitration resolution with BEAM over PM647 in AATD, confirming PM647 is in PRMEs field with no monetary damages. This removes a key investor overhang and clears the path for a Q3:26 filing, with initial data in 2027. We continue to view PRME as undervalued for the platforms potential. Buy. PRME announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, with the tribunal declaring that PM647 falls within PRMEs... More
